




RealRate

PHARMACEUTICAL 2019

Pacira Biosciences Inc
Rank 192 of 361



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Pacira Biosciences Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Pacira Biosciences Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 58% points. The greatest weakness of Pacira Biosciences Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 102% points.

The company's Economic Capital Ratio, given in the ranking table, is 255%, being 5.4% points above the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	477,969
Cost of Goods Sold	86,845
Intangible Assets	62,040
Liabilities, Current	60,661
Liabilities, Non-Current	16,874
Other Assets	40,674
Other Compr. Net Income	174
Other Expenses	1,610
Other Liabilities	290,592
Other Net Income	-16,340
Other Revenues	337,277
Property and Equipment	108,670
Research and Development	55,688
Selling, General and Administrative Expense	177,265

Output Variable	Value in 1000 USD
Assets	689,353
Liabilities	368,127
Expenses	321,408
Revenues	337,277
Stockholders Equity	321,226
Net Income	-471
Comprehensive Net Income	-384
BaseVar	866,340
ECR before LimitedLiability	132%
Economic Capital Ratio	255%